Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

27 Apr 2018 13:31

RNS Number : 4299M
Canaccord Genuity Limited
27 April 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Canaccord Genuity Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Vernalis Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Connected party to the Offeree

 

(d) Date dealing undertaken:

26 April 2018

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

No

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

Ord 1p

 

 

Sell

Purchase

37,028

50,000

 

3.81p

3.8p

 

 

3.81p

3.8p

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

Date of disclosure:

27 April 2018

Contact name:

Sam Cooke

Telephone number:

020 7523 4658

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERFMGZDZNGGRZM
Date   Source Headline
27th Sep 20137:00 amRNSAppointment of Nominated Advisor and Broker
26th Sep 201311:52 amRNSHolding(s) in Company
12th Sep 20135:41 pmRNSHolding(s) in Company
29th Jul 20134:00 pmRNSHolding(s) in Company
29th Jul 20137:00 amRNSInterim results for six months ended 30 June 2013
26th Jul 20135:45 pmRNSHolding(s) in Company
26th Jul 20135:10 pmRNSHolding(s) in Company
26th Jul 20134:48 pmRNSHolding(s) in Company
12th Jul 20137:00 amRNSVernalis Initiates Phase Ib/II POC Study of V81444
11th Jul 20137:00 amRNSNotice of Results for 6 months ended 30 June 2013
8th Jul 20133:17 pmRNSHolding(s) in Company
13th Jun 20137:00 amRNSFrovatriptan data to be presented at IHC
22nd May 201311:43 amRNSResult of AGM
29th Apr 20135:10 pmRNSHolding(s) in Company
26th Apr 201311:29 amRNSTransaction of Directors
19th Apr 201312:00 pmRNSTransaction by Directors
17th Apr 20139:22 amRNSNotice of Annual Report and AGM
16th Apr 201312:24 pmRNSTransactions of Directors/Applicable Employees
10th Apr 20137:00 amRNSAnnouncement of Results for year ended 31/12/12
21st Mar 20137:00 amRNSNotice of Results
19th Mar 20135:34 pmRNSHolding(s) in Company
6th Mar 20137:15 amRNSVernalis and Servier Extend Oncology Collaboration
6th Mar 20137:00 amRNSFirst Product in Cough Cold Pipeline Achieves POC
4th Mar 20137:00 amRNSVernalis received a further $2.5m from Genentech
8th Feb 20134:10 pmRNSHolding(s) in Company
4th Feb 20137:00 amRNSVernalis receives $1.5 m milestone from Genentech
7th Jan 20137:00 amRNSVernalis and Servier Achieve Research Milestone
2nd Jan 20138:36 amRNSVernalis and Lundbeck Achieve Third Milestone
12th Dec 20127:00 amRNSPositive Results Achieved in RO Study of V81444
20th Sep 20127:00 amRNSVernalis & Servier Achieve Research Milestone
4th Sep 20127:00 amRNSDirector/PDMR Shareholding
22nd Aug 20127:00 amRNSVernalis Initiates V81444 Receptor Occupancy Study
13th Aug 20127:00 amRNSVernalis to present at 14th World Congress on Pain
10th Aug 20122:56 pmRNSHolding(s) in Company
1st Aug 20127:00 amRNSInterim Results for six months ended 30 June 2012
10th Jul 201210:00 amRNSNotice of Results
1st Jun 201210:00 amRNSAUY922 Abstracts Accepted for Presentation at ASCO
30th May 20127:46 amRNSDirector/Applicable Employee Shareholding
22nd May 201212:50 pmRNSResult of AGM
2nd May 20127:00 amRNSSuccessful Outcome for V81444 in Phase I Study
27th Apr 20128:00 amRNSCancellation Vernalis Plc
27th Apr 20127:00 amRNSADMISSION OF SHARES TO AIM
26th Apr 20125:38 pmRNSChange of Registered Office
25th Apr 20127:00 amRNSVernalis and Servier Achieve Research Milestone
18th Apr 20125:05 pmRNSNotice of Annual Report and Annual General Meeting
3rd Apr 20127:00 amRNSAnnouncement of Results year ended 31 Dec 2011
27th Mar 20127:00 amRNSSchedule 1 - Vernalis plc
27th Mar 20127:00 amRNSCancellation of Listing/Proposed Admission to AIM
14th Mar 20127:00 amRNSNotice of Results
9th Mar 20125:07 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.